Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada Says Teriparatide Roll-Out Has Been Successful

German Firm Launched In European Markets In August Last Year

Executive Summary

Seven months after introducing its teriparatide biosimilar to Eli Lily’s Forsteo into many European markets, Stada is pleased with results and says doctors and patients alike have responded well.

You may also be interested in...



Pfenex And Alvogen Forsteo Biosimilars Primed For EU Market

Shortly after announcing the launch of Bonsity (teriparatide) in the US, Pfenex and Alvogen have picked up positive opinions from the EMA’s CHMP for their teriparatide biosimilar. However, Accord Healthcare has withdrawn its own application following concerns raised by the agency.

Bortezomib Booms For Stada As Russian Problem Remains

With group sales rising by double digits in 2019, Stada says it has the firepower to accelerate investment not only in the firm’s own product development but also broadly into external co-development and product in-licensing, to support sustainability and long-term growth.

Pfenex Still Waiting For FDA Teriparatide Equivalence Designation

Hailing the past year as a "transformational period" in which "we moved towards being a business with an FDA-approved product nearing commercialization," Pfenex ended 2019 in profit and with cash in the bank, as it eyes the potential for a monopoly in the follow-on teriparatide market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel